5.44
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com South Africa
Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan
Is Aldeyra Therapeutics Inc. a good long term investmentHigh-margin investment plays - jammulinksnews.com
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
What drives Aldeyra Therapeutics Inc. stock priceHigh-impact stock picks - jammulinksnews.com
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
FDA accepts Aldeyra's resubmitted reproxalap NDA - Eyes On Eyecare
FDA accepts for review Aldeyra Therapeutics’ resubmitted new drug application for reproxalap - Optometry Times
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Aldeyra Therapeutics Announces FDA Acceptance for Review of Repr - GuruFocus
Aldeyra says dry eye therapy undergoes FDA review (ALDX:NASDAQ) - Seeking Alpha
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease - Lelezard
FDA Accepts Aldeyra’s Reproxalap Application for Review - TipRanks
FDA Reviews Aldeyra's (ALDX) Reproxalap for Dry Eye Disease | AL - GuruFocus
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug By Investing.com - Investing.com Nigeria
FDA accepts Aldeyra’s resubmitted NDA for dry eye disease drug - Investing.com
FDA Reviews Breakthrough Dry Eye Drug: Aldeyra's Reproxalap Could Transform Treatment Landscape - Stock Titan
How Aldeyra Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
why aldeyra therapeutics inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser
What makes Aldeyra Therapeutics Inc. stock price move sharplyCapital Safe Smart Trades - Newser
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
(ALDX) Trading Report - news.stocktradersdaily.com
Aldeyra Therapeutics Leads The Pack Among 3 Promising Penny Stocks - simplywall.st
Market Sentiment Around Loss-Making Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - simplywall.st
Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data - Seeking Alpha
Aldeyra Shares Climb on FDA Backing for PVRL Drug Trial Design - MSN
Aldeyra Therapeutics (ALDX) Gets a Buy from JonesTrading - The Globe and Mail
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma | ALDX Stock News - GuruFocus
Aldeyra receives FDA special protocol assessment for lymphoma drug - Investing.com
Aldeyra receives FDA special protocol assessment for lymphoma drug By Investing.com - Investing.com Canada
Aldeyra (ALDX) Gains FDA Nod for New Cancer Trial | ALDX Stock N - GuruFocus
When the Price of (ALDX) Talks, People Listen - news.stocktradersdaily.com
Aldeyra Therapeutics Resubmits Reproxalap NDA in Dry Eye Disease - HCPLive
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):